Skip to main content
Healx logo

Healx

Updated Mar 24, 2026

A deep look at Healx's finances, team, and market position in the AI Healthcare space.

🇬🇧United KingdomSeries BAI Healthcare

Out of 100

🇬🇧

HQ

United Kingdom

🗓

Founded

2014

💰

Raised

$47M

🏷️

Stage

Series B

👥

Team

1-50

Healx uses AI to identify and develop treatments for rare diseases, applying graph neural networks and multi-omics data analysis to repurpose existing approved drugs for new orphan disease indications. The Cambridge-based company focuses exclusively on rare diseases, where the small patient populations and limited existing literature make traditional drug discovery economically unviable without

Is this your company? Claim it →

Key Facts

  • Healx has raised a total of $47M in disclosed funding across 3 funding rounds.
  • Healx was founded in 2014 by Tim Guilliams and is headquartered in United Kingdom.
  • Healx employs approximately 1-50 people.
  • Healx operates in the AI Healthcare category and is currently at the Series B stage.
  • Healx has an Awaira Score of 55/100, ranking it among the tracked AI companies on Awaira.
  • Healx's most recent funding round was a Series B of $32.9M closed in February 2017.

Source: Awaira · Updated Mar 24, 2026

N/A

Post-money

$47M

All rounds

55/100

2014

1-50 employees

Strengths

Growing team of 1-50 employees

Established market presence (founded 2014)

Considerations

!

Valuation not publicly disclosed

Analysis based on publicly available data. Not investment advice.

3

Total Rounds

$15.67M

Avg Round Size

2.7yr

Funding Span

Healx raised 3 rounds over 2.7 years, averaging $15.67M per round — a pace of roughly one round every 11 months.

⚠️ ESTIMATE
💵Est. Annual Revenue
$5M–$20M estimated ARR

Awaira estimate based on public data. Not financial advice.

How does Healx stack up against competitors?

MetricHealxButterfly NetworkTempusAlan
Awaira Score55/10085/10084/10083/100
Total Raised$47M$370M$1.05B$750M
ValuationN/A$957M$8.1B$5.83B
StageSeries BPublicPublicSeries D
Founded2014201120152016
Employees1-50500-10002500500-1000
Country🇬🇧🇺🇸🇺🇸🇫🇷
T

Tim Guilliams

Founder & CEO

View founder profile →
StageSeries B
Employees1-50
Country🇬🇧 United Kingdom
Connect
Inactive
3 rounds
Series BLatest

$32.9M

Feb 2017

Series A

$10.34M

Oct 2015

Seed

$3.76M

Jun 2014

Frequently Asked Questions

What is Healx's valuation?
There's no publicly available valuation data at this time. As a Series B company in AI Healthcare, the market value remains undetermined.
Who invested in Healx?
No confirmed investors have been publicly linked to this company yet. This section will be updated when new data surfaces.
When did Healx last raise funding?
Capital was most recently raised through a Series B of $32.9M in February 2017.
How many employees does Healx have?
Around 1-50 people work there, with headquarters in United Kingdom.
What does Healx do?
Healx uses AI to identify and develop treatments for rare diseases, applying graph neural networks and multi-omics data analysis to repurpose existing approved drugs for new orphan disease indications. The Cambridge-based company focuses exclusively on rare diseases, where the small patient populations and limited existing literature make traditional drug discovery economically unviable without computational approaches that can extract signal from sparse data. Founded in 2014, Healx is categorized under AI Healthcare.
Who founded Healx?
Behind the company is Tim Guilliams, who got it off the ground in 2014 in United Kingdom. Tim Guilliams serves as Founder & CEO.
Is Healx profitable?
There's no public reporting on profitability. With raised $47M in total funding, the company remains at the Series B stage.
Where is Healx headquartered?
Based in United Kingdom 🇬🇧, the company runs its operations in the AI Healthcare space and was established in 2014.
⚔️

Compare Healx

See how Healx stacks up against competitors in valuation, funding, team size, and Awaira Score.

Browse all comparisons →